KNSA | Ticker Profile - Titan Protect

KNSA

Kiniksa Pharmaceuticals International, plc

Healthcare · Drug Manufacturers - Specialty & Generic · NMS

$48.42

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$4.0B

Total market value of the company

Trailing P/E

56.97

Expensive — high growth expected

Forward P/E

29.50

Based on estimated future earnings — lower means cheaper

Rev Growth

+55.5%

Year-over-year revenue change

Profit Margin

9.7%

How much profit the company keeps from each dollar of revenue

ROE

13.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$62.00

+28% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 8 analysts covering this stock

About Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

https://www.kiniksa.com

Country: United Kingdom Employees: 366 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

1.295

Excellent risk-adjusted returns

Kelly Fraction

0.1168

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.919

Returns exceed worst-case losses — strong risk profile

Annual Return

65.5%

Historical annualised return based on price data

Max Drawdown

-34.1%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.17

Very low correlation to market moves

52W High

$59.87

19% below the year high

52W Low

$26.27

84% above the year low

Avg Volume

705,795

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

8.4%

Moderate short interest

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.91

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

1.49

Meaningful debt load — monitor closely

Current Ratio

3.79

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

3.14

Like current ratio but excludes inventory — stricter test

Gross Margin

54.7%

Revenue left after cost of goods — higher means pricing power

Operating Margin

13.7%

Profit from core operations before interest and tax

Free Cash Flow

$118M

Positive — the business generates more cash than it spends

Revenue (TTM)

$754M

Total revenue over the last 12 months

Net Income

$73M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$72.00

Target Median

$62.00

Target Low

$57.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go